PANACEABIO.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:59):

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India...

Stats
Today's Volume	70 774.00
Average Volume	179 533
Market Cap	8.15B
EPS	INR0 ( 2024-04-29 )
Last Dividend	INR0.750 ( 2011-09-19 )
Next Dividend	INR0 ( N/A )
P/E	-66.88
ATR14	INR0.238 (0.18%)

Volume Correlation

Long: -0.12 (neutral)

Short: -0.38 (neutral)

Signal:(44.997) Neutral

Panacea Biotec Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Panacea Biotec Limited Correlation - Currency/Commodity

0.60
( weak )

0.72
( moderate )

0.41
( neutral )

0.72
( moderate )

0.65
( moderate )

-0.83
( strong negative )

Panacea Biotec Limited Financials

Annual	2022
Revenue:	INR4.60B
Gross Profit:	INR2.07B (45.07 %)
EPS:	INR-5.51

FY	2022
Revenue:	INR4.60B
Gross Profit:	INR2.07B (45.07 %)
EPS:	INR-5.51

FY	2022
Revenue:	INR6.59B
Gross Profit:	INR3.59B (54.49 %)
EPS:	INR175.98

FY	2021
Revenue:	INR6.18B
Gross Profit:	INR3.89B (63.00 %)
EPS:	INR-24.11

Financial Reports:

No articles found.

Panacea Biotec Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Panacea Biotec Limited Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.040 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2002-08-13
Last Dividend	INR0.750	2011-09-19
Next Dividend	INR0	N/A
Payout Date	2011-10-10
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	INR8.50	--
Avg. Dividend % Per Year	0.00%	--
Score	0.73	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.040
Div. Directional Score	0.470	--

Next Divdend (Est)
(2024-05-17)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.73

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TATAINVEST.NS	Dividend Junior	2023-06-12	Annually	27	1.85%
NIPPOBATRY.NS	Dividend Junior	2023-09-20	Annually	23	1.06%
INDIANB.NS	Dividend Junior	2023-06-12	Annually	18	1.99%
CIPLA.NS	Dividend Junior	2023-07-20	Annually	28	0.41%
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
M&MFIN.NS	Dividend Junior	2023-07-20	Annually	19	1.20%
GLOBUSSPR.NS	Dividend Junior	2023-07-14	Sporadic	15	0.36%
ASTEC.NS	Dividend Junior	2023-07-20	Annually	15	0.08%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PERSISTENT.NS	Dividend Knight	2023-07-11	Semi-Annually	15	0.67%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0222	1.500	-0.445	-0.667	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0145	1.500	-1.273	-1.909	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.63	1.000	-0.137	-0.137	[3 - 30]
operatingCashFlowPerShareTTM	12.22	2.00	5.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.22	2.00	3.89	7.78	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.484	1.000	5.27	5.27	[0.2 - 0.8]
operatingProfitMarginTTM	-0.107	1.000	-4.14	-4.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.101

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-68.86	1.000	-7.06	0	[1 - 100]
returnOnEquityTTM	-0.0145	2.50	-0.818	-1.909	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.22	2.00	5.93	7.78	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.22	2.00	5.93	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.460	1.500	-6.40	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.136	1.000	9.11	0	[0.1 - 0.5]
Total Score				1.040

Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.